| Abstract | Highly active antiretroviral therapy (HAART) has dramatically reduced mortality from HIV infection, transforming it in many cases to a chronic condition. However, protease inhibitors (PIs), which are integral components of most HAART regimens, are commonly associated with a host of metabolic disturbances that may increase the risk of cardiovascular disease in patients with HIV infection, potentially counteracting some of the positive health effects of PIs. Dyslipidemia is of particular concern. The Adult AIDS Clinical Trials Group has established preliminary guidelines to evaluate and treat PI-associated dyslipidemia. A number of strategies exist for the management of PI-based dyslipidemia in HAART recipients; their advantages and disadvantages should be considered when treating patients with HIV infection. |
| Authors | Joseph P Colagreco
(Affiliation: Division of Nursing, Steinhardt School of Education, New York University, USA.)
|
| Journal | The Journal of the Association of Nurses in AIDS Care : JANAC
(J Assoc Nurses AIDS Care)
2004 Jan-Feb
Vol. 15
Issue 1
Pg. 30-41
ISSN: 1055-3290 United States |
| PMID | 14983559
(Publication Type: Journal Article, Review)
|
| Chemical References |
- Antilipemic Agents
- HIV Protease Inhibitors
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
|
| Topics |
- Antilipemic Agents
(therapeutic use)
- Antiretroviral Therapy, Highly Active
(adverse effects, methods, nursing)
- Cardiovascular Diseases
(chemically induced, therapy)
- Drug Interactions
- HIV Protease Inhibitors
(adverse effects, supply & distribution)
- HIV-Associated Lipodystrophy Syndrome
(chemically induced)
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(therapeutic use)
- Hyperlipidemias
(chemically induced)
- Insulin Resistance
- Nurse's Role
- Patient Care Planning
- Risk Factors
|
